Propanc BiopharmaPPCB -2.70%29 EV-to-EBITDA is -0.30 as of Jul. 08, 2026. GuruFocus rates PPCB with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 390 Biotechnology companies, Propanc Biopharma ranks worse than 256410% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Propanc Biopharma's enterprise value is $5.23 Mil.
Propanc Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-17.68 Mil. Therefore, Propanc Biopharma's EV-to-EBITDA for today is -0.30.
The historical rank and industry rank for Propanc Biopharma's EV-to-EBITDA or its related term are showing as below:
PPCB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.31 Med: 0 Max: 0
Current: -0.3
PPCB's EV-to-EBITDA is ranked worse than 100% of 390
companies
in the Biotechnology industry
Industry Median: 13.095
vs PPCB: -0.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Propanc Biopharma's PE Ratio (TTM) for today is calculated as:
Propanc Biopharma's share price for today is $1.845.
Propanc Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.456.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Propanc Biopharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Propanc Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Propanc Biopharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Propanc Biopharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Propanc Biopharma's EV-to-EBITDA falls into.
Propanc Biopharma's current Enterprise Value is $5.23 Mil.
Propanc Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Propanc Biopharma (PPCB) has a EV-to-EBITDA of -0.30 as of Jul. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Propanc Biopharma. According to the industry distribution chart, Propanc Biopharma ranks #999999 out of 390 companies in the Biotechnology industry.
Is Propanc Biopharma's EV-to-EBITDA too high?
Propanc Biopharma's current EV-to-EBITDA is -0.30. Based on the distribution chart, Propanc Biopharma ranks #999999 out of 390 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Propanc Biopharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Propanc Biopharma's EV-to-EBITDA compare to GRI and BGMS?
According to the Biotechnology industry distribution chart, Propanc Biopharma ranks #999999 out of 390 companies for EV-to-EBITDA. This places Propanc Biopharma in the lower half of its industry. The industry median EV-to-EBITDA is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.10, based on 390 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Propanc Biopharma. For the Biotechnology industry, the median EV-to-EBITDA is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Propanc Biopharma's current EV-to-EBITDA is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Propanc Biopharma stock overvalued right now?
Propanc Biopharma (PPCB) has a current EV-to-EBITDA of -0.30. The current EV-to-EBITDA is -0.30. Propanc Biopharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Propanc Biopharma (PPCB), the current EV-to-EBITDA is -0.30 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score
Get the complete analysis for PPCB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PPCB has been successfully added to your 
